215 related articles for article (PubMed ID: 34641612)
1. Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs.
Panagiotopoulos AA; Karakasiliotis I; Kotzampasi DM; Dimitriou M; Sourvinos G; Kampa M; Pirintsos S; Castanas E; Daskalakis V
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641612
[TBL] [Abstract][Full Text] [Related]
2. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL
Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q
Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675
[TBL] [Abstract][Full Text] [Related]
3. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
4. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
5.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
[TBL] [Abstract][Full Text] [Related]
8.
Bung N; Krishnan SR; Bulusu G; Roy A
Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764
[No Abstract] [Full Text] [Related]
9. Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host.
Agrawal S; Pathak E; Mishra R; Mishra V; Parveen A; Mishra SK; Byadgi PS; Dubey SK; Chaudhary AK; Singh V; Chaurasia RN; Atri N
Comput Biol Med; 2022 Oct; 149():106049. PubMed ID: 36103744
[TBL] [Abstract][Full Text] [Related]
10. Discovery of SARS-CoV-2 3CL
Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
[TBL] [Abstract][Full Text] [Related]
13. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
[TBL] [Abstract][Full Text] [Related]
14. Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2.
Al-Karmalawy AA; Farid MM; Mostafa A; Ragheb AY; H Mahmoud S; Shehata M; Shama NMA; GabAllah M; Mostafa-Hedeab G; Marzouk MM
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770969
[TBL] [Abstract][Full Text] [Related]
15. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Activity of Flavonoid Scaffolds on SARS-CoV-2 3CL
Khamto N; Utama K; Boontawee P; Janthong A; Tatieng S; Arthan S; Choommongkol V; Sangthong P; Yenjai C; Suree N; Meepowpan P
J Chem Inf Model; 2024 Feb; 64(3):874-891. PubMed ID: 38277124
[TBL] [Abstract][Full Text] [Related]
17. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
18. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
Viruses; 2021 May; 13(5):. PubMed ID: 34068686
[TBL] [Abstract][Full Text] [Related]
19. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
[TBL] [Abstract][Full Text] [Related]
20. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
